DPYD genotyping implementation study published
In a journal article published online last week in The Lancet Oncology, Henricks et al. reported that DPYD genotype-based dose reductions of fluorouracil and capecitabine in cancer patients resulted in improved safety outcomes and was feasible in clinical practice.
The authors prospectively genotyped four DPYD variants: rs3918290 (1905+1G>